TY - JOUR
T1 - Hemoglobin level associates with survival in women from Appalachian Kentucky with uterine cervix cancer
AU - Kunos, Charles A.
AU - Fabian, Denise
AU - Fredericks, Tricia
AU - Baldwin, Lauren
AU - Dietrich, Charles
AU - Miller, Rachel W.
AU - Ueland, Frederick R.
N1 - Publisher Copyright:
Copyright © 2023 Kunos, Fabian, Fredericks, Baldwin, Dietrich, Miller and Ueland.
PY - 2023
Y1 - 2023
N2 - Introduction: The purpose of this retrospective study was to determine the relationship between pretherapy hemoglobin levels and progression-free survival among women with uterine cervix cancer undergoing concurrent weekly cisplatin and radiotherapy followed by brachytherapy. Methods: Patients with advanced-stage II-IVA uterine cervix cancer were grouped by hemoglobin level (Hgb ≥ 12.0, 11.9-10.0, or < 10.0 g/dL). Endpoints were progression-free survival, overall survival, and local control. Results: Between 01/2001 and 07/2022, 168 patients contributed demographic, tumor, pretherapy hemoglobin, and outcome data with a median follow-up of 31 months. Progression-free survival at three years was 73% (95% confidence interval: 58%-84%), 71% (95% confidence interval: 56%-82%), and 62% (95% confidence interval: 44%-75%) for the Hgb ≥ 12.0, 11.9-10.0, or < 10.0 g/dL groups, respectfully (P < 0.001). In addition, pretherapy hemoglobin levels were significant with treatment outcome when included in a multivariate analysis of prognostic variables. Discussion: In conclusion, the difference in pretherapy hemoglobin level was prognostic of progression-free survival.
AB - Introduction: The purpose of this retrospective study was to determine the relationship between pretherapy hemoglobin levels and progression-free survival among women with uterine cervix cancer undergoing concurrent weekly cisplatin and radiotherapy followed by brachytherapy. Methods: Patients with advanced-stage II-IVA uterine cervix cancer were grouped by hemoglobin level (Hgb ≥ 12.0, 11.9-10.0, or < 10.0 g/dL). Endpoints were progression-free survival, overall survival, and local control. Results: Between 01/2001 and 07/2022, 168 patients contributed demographic, tumor, pretherapy hemoglobin, and outcome data with a median follow-up of 31 months. Progression-free survival at three years was 73% (95% confidence interval: 58%-84%), 71% (95% confidence interval: 56%-82%), and 62% (95% confidence interval: 44%-75%) for the Hgb ≥ 12.0, 11.9-10.0, or < 10.0 g/dL groups, respectfully (P < 0.001). In addition, pretherapy hemoglobin levels were significant with treatment outcome when included in a multivariate analysis of prognostic variables. Discussion: In conclusion, the difference in pretherapy hemoglobin level was prognostic of progression-free survival.
KW - Appalachia
KW - cervical cancer
KW - hemoglobin
KW - survival
KW - uterine cervix
UR - http://www.scopus.com/inward/record.url?scp=85165210815&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85165210815&partnerID=8YFLogxK
U2 - 10.3389/fonc.2023.1132135
DO - 10.3389/fonc.2023.1132135
M3 - Article
AN - SCOPUS:85165210815
SN - 2234-943X
VL - 13
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 1132135
ER -